株式会社グローバルインフォメーション
TEL: 044-952-0102
表紙
市場調査レポート

感染症ワクチン市場の業務提携:契約条件・合意内容

Global Infectious Vaccines Partnering Terms and Agreements 2010 to 2016: Deal Trends, Players and Financials

発行 Current Partnering, a division of Wildwood Ventures Limited 商品コード 253943
出版日 ページ情報 英文 447 Pages
納期: 即日から翌営業日
価格
本日の銀行送金レート: 1USD=115.18円で換算しております。
Back to Top
感染症ワクチン市場の業務提携:契約条件・合意内容 Global Infectious Vaccines Partnering Terms and Agreements 2010 to 2016: Deal Trends, Players and Financials
出版日: 2016年10月05日 ページ情報: 英文 447 Pages
概要

当レポートでは、感染症関連の各種契約−−事業提携(パートナーシップ)やその他の資本取引提携−−の契約条件の傾向について分析し、近年における各種契約の動向、大規模契約および大手製薬企業による契約の概要、契約の種類・開発段階・疾患区分・技術区分別のディレクトリなどをまとめ、概略下記の構成でお届けいたします。

エグゼクティブ・サマリー

第1章 イントロダクション

第2章 感染症ワクチン関連の資本取引動向

  • 概要
  • 感染症ワクチン関連の事業提携:過去数年間の動向
  • 大手製薬企業の感染症ワクチン関連の資本取引行動
  • 感染症ワクチン関連の資本取引行動に積極的な製薬企業
  • 感染症ワクチン関連の資本取引:取引の種類別
  • 感染症ワクチン関連の資本取引:開発段階別
  • 感染症ワクチン関連の資本取引:適応症別
  • 感染症ワクチン関連の資本取引:ワクチン/補助剤
  • パートナーシップに関する公開された取引条件
  • 感染症ワクチン関連の資本取引の構造・事例

第3章 代表的な資本取引

  • イントロダクション
  • 代表的な資本取引(取引額順のランキング)

第4章 大手製薬企業による、感染症ワクチン関連の資本取引

  • イントロダクション
  • データの活用方法について
  • 大手製薬企業の感染症ワクチン関連資本取引:企業プロファイル
    • Abbott
    • アステラス製薬
    • 第一三共
    • Gilead Sciences
    • GlaxoSmithKline
    • Johnson & Johnson
    • Merck & Co
    • Novartis
    • Pfizer
    • Purdue
    • Sanofi
    • 武田薬品工業

第5章 大手バイオテク企業による感染ワクチン関連の資本取引

第6章 感染症ワクチンの資本取引企業の一覧

  • イントロダクション
  • 関連企業・団体名(ABC順)
  • 治験の段階別
  • 取引の種類別
    • 資産買収
    • 資産譲渡
    • 大手製薬企業によるライセンス契約(outlicensing)
    • 共同開発
    • 共同研究開発(R&D)
    • 共同市場
    • 契約サービス
    • 共同プロモーション
    • 共同研究開発契約(CRADA)
    • クロスライセンス
    • 開発
    • 流通
    • 株式購入
    • 評価
    • 付与
    • ジョイントベンチャー
    • ライセンス契約
    • 訴訟
    • 製造
    • OEM
    • マーケティング
    • 資材移転
    • オプション
    • プロモーション
    • 調査
    • ロイヤルティ・ファイナンス
    • 調停
    • スピンアウト
    • サブライセンス
    • 供給
    • 技術移転
    • 終結
    • 補償
  • 感染症の治療領域
  • 関連技術別

第7章 提携リソースセンター

  • オンライン・パートナーシップ
  • パートナーリングイベント
  • 関連資料

付録

図表一覧

このページに掲載されている内容は最新版と異なる場合があります。詳細はお問い合わせください。

目次
Product Code: CP22061

The Global Infectious Vaccines Partnering Terms and Agreements 2010 to 2016: Deal trends, players and financials report provides a detailed understanding and analysis of how and why companies enter infectious vaccines partnering deals. The majority of deals are development stage whereby the licensee obtains a right or an option right to license the licensors vaccine technology. These deals tend to be multicomponent, starting with collaborative R&D, and commercialization of outcomes. The report also includes adjuvant deals and alliances.

This report provides details of the latest infectious vaccines agreements announced in the healthcare sectors.

Understanding the flexibility of a prospective partner's negotiated deals terms provides critical insight into the negotiation process in terms of what you can expect to achieve during the negotiation of terms. Whilst many smaller companies will be seeking details of the payments clauses, the devil is in the detail in terms of how payments are triggered - contract documents provide this insight where press releases and databases do not.

This report contains a comprehensive listing of all infectious vaccines partnering deals announced since January 2010, including financial terms where available, including over 600 links to online deal records of actual infectious vaccines partnering deals as disclosed by the deal parties. In addition, where available, records include contract documents as submitted to the Securities Exchange Commission by companies and their partners.

The initial chapters of this report provide an orientation of Infectious Vaccines dealmaking and business activities.

Chapter 1 provides an introduction to the report, whilst chapter 2 provides an overview of the trends in Infectious Vaccines dealmaking since 2010, including details of average headline, upfront, milestone and royalty terms. Infectious Vaccines deals since 2010. Deals are listed by headline value, signed by big pharma, most active Infectious Vaccines dealmaking companies. Where the deal has an agreement contract published at the SEC a link provides online access to the contract.

Chapter 3 provides a review of the leading Infectious Vaccines deals since 2010. Deals are listed by headline value, signed by big pharma, most active Infectious Vaccines dealmaking companies. Where the deal has an agreement contract published at the SEC a link provides online access to the contract.

Chapter 4 provides a comprehensive listing of the top 25 most active companies in Infectious Vaccines dealmaking with a brief summary followed by a comprehensive listing of Infectious Vaccines deals, as well as contract documents available in the public domain. Where available, each deal title links via Weblink to an online version of the actual contract document, providing easy access to each contract document on demand.

Chapter 5 provides a comprehensive and detailed review of Infectious Vaccines partnering deals signed and announced since Jan to 2010, where a contract document is available in the public domain. The chapter is organized by company A-Z, deal type (collaborative R&D, co-promotion, licensing etc), and specific therapy focus. Each deal title links via Weblink to an online version of the deal record and where available, the contract document, providing easy access to each contract document on demand.

Chapter 6 provides a comprehensive and detailed review of Infectious Vaccines partnering deals signed and announced since Jan to 2010. The chapter is organized by specific Infectious Vaccines technology type in focus. Each deal title links via Weblink to an online version of the deal record and where available, the contract document, providing easy access to each contract document on demand.

In addition, a comprehensive appendix is provided organized by Infectious Vaccines partnering company A-Z, deal type definitions and Infectious Vaccines partnering agreements example. Each deal title links via Weblink to an online version of the deal record and where available, the contract document, providing easy access to each contract document on demand. The report also includes numerous tables and figures that illustrate the trends and activities in Infectious Vaccines partnering and dealmaking since 2010.

In conclusion, this report provides everything a prospective dealmaker needs to know about partnering in the research, development and commercialization of Infectious Vaccines technologies and products.

Report scope

Global Infectious Vaccines Partnering Terms and Agreements 2010 to 2016: Deal trends, players and financials is intended to provide the reader with an in-depth understanding and access to infectious vaccines trends and structure of deals entered into by leading companies worldwide.Global Infectious Vaccines Partnering Terms and Agreements 2010 to 2016: Deal trends, players and financials includes:

  • Trends in infectious vaccines dealmaking in the biopharma industry since 2010
  • Analysis of infectious vaccines deal structure
  • Access to headline, upfront, milestone and royalty data
  • Access to over 600 infectious vaccines deal records
  • Identify the most active infectious vaccine dealmakers since 2010
  • The leading infectious vaccines deals by value since 2010
  • Includes adjuvant deals and alliances since 2010

In Global Infectious Vaccines Partnering Terms and Agreements 2010 to 2016: Deal trends, players and financials, the available deals are listed by:

  • Company A-Z
  • Headline value
  • Stage of development at signing
  • Deal component type
  • Specific infectious therapy target

Each deal title links via Weblink to an online version of the deal record and where available, the contract document, providing easy access to each contract document on demand.

The Global Infectious Vaccines Partnering Terms and Agreements 2010 to 2016: Deal trends, players and financials report provides comprehensive access to available deals and contract documents for over 500 infectious vaccines deals. Analyzing actual contract agreements allows assessment of the following:

  • What are the precise rights granted or optioned?
  • What is actually granted by the agreement to the partner company?
  • What exclusivity is granted?
  • What is the payment structure for the deal?
  • How aresalesand payments audited?
  • What is the deal term?
  • How are the key terms of the agreement defined?
  • How are IPRs handled and owned?
  • Who is responsible for commercialization?
  • Who is responsible for development, supply, and manufacture?
  • How is confidentiality and publication managed?
  • How are disputes to be resolved?
  • Under what conditions can the deal be terminated?
  • What happens when there is a change of ownership?
  • What sublicensing and subcontracting provisions have been agreed?
  • Which boilerplate clauses does the company insist upon?
  • Which boilerplate clauses appear to differ from partner to partner or deal type to deal type?
  • Which jurisdiction does the company insist upon for agreement law?

Benefits

Infectious Vaccines Partnering Terms and Agreements provides the reader with the following key benefits:

  • In-depth understanding of infectious vaccines deal trends since 2010
  • Access infectious vaccines deal headline, upfront, milestone and royalty data
  • Analysis of the structure of infectious vaccines agreements with numerous real life case studies
  • Comprehensive access to over 600 links to actual infectious vaccines deals entered into by the world's biopharma companies, together with real world clause examples
  • Identify leading infectious vaccines deals by value since 2010
  • Identify the most active infectious vaccines dealmakers since 2010
  • Insight into the terms included in infectious vaccines agreement, together with real world clause examples
  • Understand the key deal terms companies have agreed in previous deals
  • Undertake due diligence to assess suitability of your proposed deal terms for partner companies

Table of Contents

Executive Summary

Chapter 1 - Introduction

Chapter 2 - Trends in Infectious Vaccines dealmaking

  • 2.1. Introduction
  • 2.2. Infectious Vaccines partnering over the years
  • 2.3. Most active Infectious Vaccines dealmakers
  • 2.4. Infectious Vaccines partnering by deal type
  • 2.5. Infectious Vaccines partnering by therapy area
  • 2.6. Deal terms for Infectious Vaccines partnering
    • 2.6.1 Infectious Vaccines partnering headline values
    • 2.6.2 Infectious Vaccines deal upfront payments
    • 2.6.3 Infectious Vaccines deal milestone payments
    • 2.6.4 Infectious Vaccines royalty rates

Chapter 3 - Leading Infectious Vaccines deals

  • 3.1. Introduction
  • 3.2. Top Infectious Vaccines deals by value

Chapter 4 - Most active Infectious Vaccines dealmakers

  • 4.1. Introduction
  • 4.2. Most active Infectious Vaccines dealmakers
  • 4.3. Most active Infectious Vaccines partnering company profiles

Chapter 5 - Infectious Vaccines contracts dealmaking directory

  • 5.1. Introduction
  • 5.2. Infectious Vaccines contracts dealmaking directory

Chapter 6 - Infectious Vaccines dealmaking by technology type

Chapter 7 - Partnering resource center

  • 7.1. Online partnering
  • 7.2. Partnering events
  • 7.3. Further reading on dealmaking

Appendices

Appendix 1 - Infectious Vaccines deals by company A-Z

Appendix 2 - Infectious Vaccines deals by stage of development

  • Discovery
  • Preclinical
  • Phase I
  • Phase II
  • Phase III
  • Regulatory
  • Marketed
  • Formulation

Appendix 3 - Infectious Vaccines deals by deal type

  • Asset purchase
  • Assignment
  • Bigpharma outlicensing
  • Co-development
  • Collaborative R&D
  • Co-market
  • Co-promotion
  • CRADA
  • Development
  • Distribution
  • Equity purchase
  • Evaluation
  • Grant
  • Joint venture
  • Licensing
  • Manufacturing
  • Marketing
  • Option
  • Promotion
  • Research
  • Settlement
  • Spin out
  • Sub-license
  • Supply
  • Technology transfer
  • Termination

Appendix 4 - Infectious Vaccines deals by therapy area

Appendix 5 - Deal type definitions

About Wildwood Ventures

  • Current Partnering
  • Current Agreements
  • Recent report titles from Current Partnering

Table of figures

  • Figure 1: Infectious Vaccines partnering since 2010
  • Figure 2: Active Infectious Vaccines dealmaking activity- 2010 to 2016
  • Figure 3: Infectious Vaccines partnering by deal type since 2010
  • Figure 4: Infectious Vaccines partnering by disease type since 2010
  • Figure 5: Infectious Vaccines deals with a headline value
  • Figure 6: Infectious Vaccines deals with an upfront value
  • Figure 7: Infectious Vaccines deals with a milestone value
  • Figure 8: Infectious Vaccines deals with a royalty rate value
  • Figure 9: Top Infectious Vaccines deals by value since 2010
  • Figure 10: Most active Infectious Vaccines dealmakers 2010 to 2016
  • Figure 11: Online partnering resources
  • Figure 12: Forthcoming partnering events
Back to Top